Detalhe da pesquisa
1.
Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques.
Mol Ther
; 23(6): 1066-1076, 2015 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-25807289
2.
HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy.
Mol Ther
; 21(4): 887-94, 2013 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-23295947
3.
ORFV: a novel oncolytic and immune stimulating parapoxvirus therapeutic.
Mol Ther
; 20(6): 1148-57, 2012 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-22273579
4.
Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine.
Mol Ther
; 20(9): 1791-9, 2012 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-22760544
5.
Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production.
Proc Natl Acad Sci U S A
; 107(4): 1576-81, 2010 Jan 26.
Artigo
Inglês
| MEDLINE | ID: mdl-20080710
6.
Oncolytic Viruses: The Best is Yet to Come.
Curr Cancer Drug Targets
; 18(2): 109-123, 2018.
Artigo
Inglês
| MEDLINE | ID: mdl-28176648
7.
Leukemia cell-rhabdovirus vaccine: personalized immunotherapy for acute lymphoblastic leukemia.
Clin Cancer Res
; 19(14): 3832-43, 2013 Jul 15.
Artigo
Inglês
| MEDLINE | ID: mdl-23714728
8.
Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow.
Mol Ther
; 15(9): 1686-93, 2007 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-17579581